Travis Walling, APRN
Adult Health · Booneville, ARNPI 1114329497
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 243 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,411 and has fallen 92.6% since, to $104 in 2025.
Across 243 payments — averaging $14.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$645
- GSK$484
- Amgen$387
- Pfizer$313
- Novo Nordisk$244
- Bayer$182
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,545100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $645 |
| GSK | 33 | $484 |
| Amgen | 22 | $387 |
| Pfizer | 23 | $313 |
| Novo Nordisk | 14 | $244 |
| Bayer | 12 | $182 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $171 |
| Lilly USA, LLC | 10 | $148 |
| AstraZeneca | 10 | $132 |
| Abbott | 8 | $119 |
| Johnson & Johnson | 7 | $111 |
| Astellas Pharma US Inc | 7 | $106 |
| Alfasigma USA, Inc. | 7 | $90 |
| Novartis | 6 | $85 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $71 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Merck | 2 | $30 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Boehringer Ingelheim | 2 | $27 |
| Philips North America LLC | 1 | $20 |
| Exact Sciences | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$3,545 in reported general payments places this provider in the 85th percentile of 154 adult health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $48,762 |
| MounjaroTirzepatide | 34 | $42,190 |
| FarxigaDapagliflozin Propanediol | 20 | $17,964 |
| OzempicSemaglutide | 13 | $16,324 |
| EntrestoSacubitril/Valsartan | 13 | $11,663 |
| MyrbetriqMirabegron | 11 | $7,631 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $4,910 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 60 | $1,872 |
| Pregabalin | 12 | $1,267 |
| Atorvastatin Calcium | 186 | $1,130 |
| Hydroxyzine Hcl | 42 | $1,111 |
| Ventolin HfaAlbuterol Sulfate | 19 | $1,030 |
| Gabapentin | 57 | $750 |
| Omeprazole | 64 | $681 |
| Metoprolol Succinate | 55 | $679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $484 | $48,76237 claims |
| Lilly USA, LLCMounjaro | $148 | $42,19034 claims |
| AstraZenecaFarxiga | $132 | $17,96420 claims |
| Novo NordiskOzempic | $244 | $16,32413 claims |
| NovartisEntresto | $85 | $11,66313 claims |
| Astellas Pharma US IncMyrbetriq | $106 | $7,63111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 154 adult health providers in Arkansas.
Other adult health in Booneville
- Holly MooreLittle Rock$59K
- Deborah ShipmanJonesboro$41K
- Lisa HurdJonesboro$12K
- Kari SchrankFayetteville$9K
- Amanda McClureFayetteville$9K
- Gina NullFort Smith$8K
- Darren CompasBentonville$8K
- Lisa HarveyHot Springs$8K
- Abby MartensSpringdale$7K
- Marie JonesFayetteville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.